The major focus has been the development of a defined, T-cell-reactive, recombinant protein vaccine. Cole GT et al in 2008 described the first genetically engineered, live, attenuated vaccine that protects both BALB/c and C57BL/6 mice against coccidioidomycosis. Two chitinase genes (CTS2 and CTS3) were disrupted to yield the attenuated strain, which was unable to endosporulate and was no longer infectious. Vaccinated survivors mounted an immune response characterized by production of both T-helper-1- and T-helper-2-type cytokines. Histology revealed well-formed granulomas and markedly diminished inflammation. Significantly fewer organisms were observed in the lungs of survivors than in those of nonvaccinated mice. However futher research is needed before we adapt these models to human beings.
Coccidioidomycosis future or investigational therapies
Zygomycosis future or investigational therapies
Histoplasmosis primary prevention
Mycobacterium abscessus primary prevention
Mucormycosis primary prevention
Mucormycosis secondary prevention
Coccidioidomycosis secondary prevention
Coccidioidomycosis cost-effectiveness of therapy